期刊文献+

罗格列酮对血管紧张素Ⅱ诱导的大鼠主动脉外膜成纤维细胞迁移的影响 被引量:1

Effects of rosiglitazone on rat aortic adventitial fibroblasts migration induced by angiotensinⅡ
下载PDF
导出
摘要 目的:探讨PPARγ激动剂罗格列酮(ROSI)对血管紧张素Ⅱ(AngⅡ)诱导的大鼠主动脉外膜成纤维细胞(AFs)迁移的影响。方法:采用组织贴块法原代培养AFs并传代。取第5代纯化细胞用于实验,分为空白对照组、AngⅡ组、AngⅡ+0.1μmol/LROSI组、AngⅡ+1.0μmol/LROSI组、AngⅡ+10μmol/LROSI组,采用TranswellChamber测试细胞迁移。另取AFs分为4组:空白对照组、AngⅡ组、AngⅡ+10μmol/L ROSI组和AngⅡ+10μmol/L ROSI+GW9662组,用Western blotting检测基质金属蛋白酶2(MMP-2)蛋白的表达。另取AFs同上分为4组,采用明胶酶谱法检测MMP-2活性。结果:AngⅡ能促进AFs的迁移,ROSI可呈剂量依赖地抑制AFs的迁移(P<0.05)。ROSI能够降低AFs MMP-2蛋白的表达及MMP-2的活性。结论:ROSI可抑制AngⅡ诱导的大鼠AFs的迁移,其机制可能与抑制MMP-2的表达及活性有关。 Aim : To explore the effect of PPARγ activators, rosiglitazone on the migration induced by angiotensin Ⅱ (Ang Ⅱ ) in cultured aortic adventitial fibroblasts (AFs). Methods:AFs were prepared from rat aortas using explant technique and cultured for passages. The fifth passage cells were used. The AFs were allocated into 5 groups: control group, Ang Ⅱ group, Ang Ⅱ + 0.1 μmol/L ROSI group, Ang Ⅱ + 1.0 μmol/L ROSI group, and Ang Ⅱ + 10 μmol/L ROSI group. Cell migration was determined by Transwell Chamber. Additionally, the AFs were allocated into 4 groups: control group, Ang Ⅱ group, Ang Ⅱ + 10 μmol/L ROSI group, and Ang Ⅱ + 10 μmol/L t/OSI + GW9662 group. The expression and activity of MMP-2 were determined by Western blotting and zymography,respectively. Results: Ang Ⅱ significantly induced the migration of AFs, which was inhibited by pretreatment with rosiglitazone in a dose-dependent manner. Rosiglitazone could attenuate the expression of MMP-2 protein and the activity of MMP-2. Conclusion : Rosiglitazone can obviously attenuate the expression and activity of MMP-2 induced by Ang Ⅱ , which may be realized by inhibiting the migration of AFs.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2008年第3期581-583,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 罗格列酮 血管紧张素Ⅱ 外膜成纤维细胞 迁移 rosiglitazone angiotensin Ⅱ adventitial fibroblasts migration
  • 相关文献

参考文献12

  • 1Faggin E, Puato M, Zardo L,et al. Smooth muscle-specific SM22 protein is expressed in the adventitial cells of balloon-injured rabbit carotid artery [ J ]. Arterioscler Thromb Vasc Biol,1999,19(6) :1393.
  • 2Cai W J, Koltai S, Kocsis E, et al. Remodeling of the adventitia during coronary arteriogenesis[ J]. Am J Physiol Heart Circ Physiol, 2003,284( 1 ) : H31.
  • 3Zhu Y, Kan L, Qi C, et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR[ J]. J Biol Chem ,2000,275 ( 18 ) : 13510.
  • 4Berger J, Mollerand DE. The mechanisms of action of PPARs[ J]. Annu Rev Med,2002 ,53 :409.
  • 5Law RE, Goetze S,Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells[ J]. Circulation, 2000,101 ( 11 ) : 1311.
  • 6Zhu DL, Herembert T, Marche P. Increased proliferation of adventitial fibroblasts from spontaneously hypertensive rat aorta[J]. J Hypertens,1991,9(12) :1161.
  • 7Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia [J]. J Clin Invest, 1996,98(8) :1897.
  • 8Herrmann J, Samee S, Chade A,et al. Differential effect of experimental hypertension and hypercholesterolemia on adventitial remodeling [ J ]. Arterioscler Thromb Vasc Biol, 2005,25 (2) :447.
  • 9Diep QN, El Mabrouk M,Cohn JS,et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin Ⅱ-infused rats: role of peroxisome proliferator-activated receptor-gamma [ J ]. Circulation, 2002,105(19) :2296.
  • 10Creemers EE,Cleutjens JP,Smits JF,et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure [ J ]. Circ Res,2001,89 ( 3 ) : 201.

同被引文献10

  • 1Yu DM, Yu P. The consideration about the cardiovascular safety of rosiglitazone [J]. J China Prescribed Drug, 2007, 7 (64): 51-53.
  • 2Nissen SE, Wolski K. Effect of Rosiglitazone on the risk of myocardial Infarction and death from cardiovascular causes [J]. N EnglJ Med, 2007, 356 (24): 2457-2471.
  • 3Khandoudi N, Delerive P, Berrebi-Bertrand I, et al. Rosiglitazone, a peroxisome proliferator-aetivated receptor-γ, inhibits the Jun NH2 terminal kinase/aetivating protein 1 pathway and protects the heart from isehemia/reperfusion injury [J]. Diabetes, 2002, 51: 1507-1514.
  • 4Molavi B, Chen JW, Mehta JL. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK [J]. Am J Physiol Heart Circ Physiol, 2006, 291: H687- H693.
  • 5Johns DG, Ao ZH, Eybye M, et al. Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat [J]. JPET, 2005, 315 (3): 1020 -1027.
  • 6Son NH, Park TS, Yamashita H, et al. Cardiomyocyte expression of PPAR7 leads to cardiac dysfunction in mice [J]. J Clini Invest, 2007, 17 (10): 2791-2801.
  • 7Chen, Ma S, Wei LX, al. Cardioprotective and antiarrhythmic effect of U50, 488H in ischemia/reperfusion rat heart [J]. Heart Vessel, 2007, 22: 335- 344.
  • 8Gao F, Yue TL, Shi DW, et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation [J]. Cadiovasc Res, 2002, 53, 414-422.
  • 9Walker MJ, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion [J]. Cardiovasc Res, 1988, 22: 447-455.
  • 10Joosen AM, Bakker AH, Kersten S, et al. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue [J]. BrJ Nutr, 2008, 99 (3): 487- 493.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部